| Business Name: |
Kuki Atsuo |
| Contact Person: |
Atsuo Kuki |
| Address: |
13009 Signature Point # 256, San Diego, California 92130 |
| Phone Number: |
(858) 699-1809 |
| Annual Revenue (USD): |
$0 to $49.999 |
| Founding Year: |
2009 |
| Location Type: |
Single Location |
| Employee Number: |
1 to 4 |
| Business Type: |
B2B & B2C |
| Business Category: |
|
| SIC Code: |
2834 |
| NAICS Code: |
325412 |
| Share This Business: |
|
| Related Businesses: |
Sunovion Pharmaceuticals Inc - San Diego, CA 92130
Ocera Therapeutics Inc - San Diego, CA 92130
Zogenix Inc - San Diego, CA 92130
Centagen - San Diego, CA 92130
Soledad Pharmaceuticals - San Diego, CA 92130
Surefire Diagnostics - San Diego, CA 92130
Mei Pharma Inc - San Diego, CA 92130
Sunovion Respiratory Development Inc - San Diego, CA 92130
Stratum Medical Corp - San Diego, CA 92130
Elcelyx Therapeutics Inc - San Diego, CA 92130
Calixa Therapeutics Inc - San Diego, CA 92130
Ingenome Inc - San Diego, CA 92130
Ader Enterprises Inc - San Diego, CA 92130
Remora Pharmaceuticals Inc - San Diego, CA 92130
Adamis Pharmaceuticals Corp - San Diego, CA 92130
Brighton Pharmaceuticals Inc - San Diego, CA 92130
Sequel Pharmaceuticals Inc - San Diego, CA 92130
Oprx Pharmaceuticals Inc - San Diego, CA 92130
Sequel Pharmaceuticals - San Diego, CA 92130
Nerveda Inc - San Diego, CA 92130
|
The company Kuki Atsuo provides BOTH services in the form of from its single location in California.
1 to 4 employees work for Kuki Atsuo, and the business now earns $0 to $49.999 per annum.
Kuki Atsuo was launched in 2009 and is classified under SIC code and category 2834 , and NAICS number and grouping 325412 .
To contact Kuki Atsuo, please call Atsuo Kuki with the phone number (858) 699-1809 or visit its single location at 13009 Signature Point # 256 in San Diego, California 92130.
The location of the single location can also be found using the coordinates 32.954923,-117.231855.
Read more details about this business on the webpage or follow the company’s social media accounts, on Twitter and on Facebook.